Skip to content
lifestyle.harcourthealth.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Aptevo Therapeutics
Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50%
March 10, 2026
Aptevo Announces Executive Leadership Transitions to Support Next Phase of Growth
February 3, 2026
←
Previous Page
1
2